Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003
Kidney | Phase I
What is the purpose of this trial?
This is an open label, multi-institutional, single arm study of dose escalation phase Ib cohort, followed by a phase II cohort of anti-PD-1 antibody MK-3475 in combination with bevacizumab. No randomization or blinding is involved.
- Trial withMerck Sharp & Dohme LLC
- Start Date09/01/2022
- End Date12/05/2019
- Last Updated01/24/2023
- Study HIC#2000029978